| | A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malign...A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors - Full ... |
|
|
Conditions: Malignancy; Non-hodgkin Lymphoma; Multiple Myeloma; Breast Cancer; Ovarian Cancer; Soft Tissue Sarcoma; Squamous Cell Carcinoma; Head and Neck Cancer; DLBCL; Mantle Cell Lymphoma; Follicular Lymphoma; Leiomyosarcoma; Pancreatic Cancer; Sarcoma; CLLIntervention: Drug: CYT-0851Sponsor: Cyteir Therapeutics, Inc.Not yet recruiting
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου